ArticleJournal of applied clinical medical physics2026
A hybrid deep learning framework for automated treatment planning in cervical cancer radiotherapy.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRadiation therapy treatment planning is a time-consuming trial-and-error process, and the plan quality is heavily dependent on planners' experiences, resulting in a strong demand for automated planning methods that can rapidly generate uniformly high-quality plans. PURPOSE: This study aimed to develop a hybrid automated deep learning-based plan optimization (HALO) framework, integrating deep learning fluence prediction and optimization, multileaf collimator (MLC) sequencing, and GPU-accelerated Monte Carlo dose computation. HALO was designed to ensure robust plan generation for cervical cancer intensity-modulated radiation therapy (IMRT).
methodsThe proposed HALO framework incorporated several functional modules. First, a dose-guided Fluence Prediction Network (DG-FPN) was developed. A total of 120 cervical cancer clinical IMRT plans were collected to train the DG-FPN, of which 90 plans were assigned for training, 10 for validation, and 20 for testing. The neural network took patients' computed tomography (CT) anatomy as input and predicted the 3D dose distribution and fluence maps. Next, the predicted fluence maps were further optimized to meet dose-volume constraints (DVCs), and then the refined fluence maps were converted into deliverable segments using an MLC sequencing algorithm. Finally, dose calculation was performed using a GPU-accelerated Monte Carlo engine. The 20 patients in the testing set were used to evaluate the HALO method, and the plan deliverability was validated by patient-specific IMRT Quality Assurance (QA).
resultsThe DG-FPN achieved superior fluence prediction accuracy compared to previous work, with a median mean absolute error (MAE) of 0.055 and a structural similarity index (SSIM) of 0.94. The automated framework generated high-quality plans and reduced dose to adjacent OARs, with V
conclusionsThis study demonstrated the clinical feasibility of the proposed HALO framework for cervical cancer radiotherapy in producing high-quality and deliverable IMRT plans. The proposed automated paradigm can serve as a stand-alone platform for treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.